Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...

The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.

New research highlights a pivotal role for the p53 gene in ulcerative colitis progression, offering a potential therapeutic ...

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated ...

New research from Denmark sheds light on why ulcerative colitis affects patients differently, moving us closer to ...

DRB1*01:03 allele was significantly associated with increased severity of ulcerative colitis, including higher rates of ...

Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from ...

DRB1*01:03 genetic variant is associated with severe ulcerative colitis, significantly raising the risk of major surgeries ...

Innovent Biologics has reported that its trial of picankibart (IBI112) in Chinese patients with ulcerative colitis met the ...

Researchers in Michael Sigal’s lab at the Max Delbruck Center and Charite – Universitatsmedizin Berlin have discovered the ...